Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson

Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson


Andy Jassy, chief executive officer of Amazon.Com Inc., during the GeekWire Summit in Seattle, Washington, U.S., on Tuesday, Oct. 5, 2021.

David Ryder | Bloomberg | Getty Images

Amazon is developing cancer vaccines in collaboration with the Fred Hutchinson Cancer Research Center, and it recently launched an FDA-approved clinical trial.

Amazon and Fred Hutchinson are looking to recruit 20 participants over the age of 18 for the early stage, or phase 1, trial, according to a filing on clinicaltrials.gov, a database of clinical trials run by the National Library of Medicine. The goal is to develop “personalized vaccines” that can treat breast cancer and melanoma, a form of skin cancer, the filing states.

Fred Hutchinson is listed as a sponsor of the study, while Amazon is listed as a collaborator, according to the filing. News of the partnership was first reported by Business Insider. The study was first posted last October, and it began June 9. It’s expected to be complete by Nov. 1 of 2023.

Fred Hutch and Amazon confirmed the partnership. An Amazon spokesperson said it’s being led by Fred Hutch.

“Amazon is contributing scientific and machine learning expertise to a partnership with Fred Hutch to explore the development of a personalized treatment for certain forms of cancer,” the spokesperson told CNBC in a statement. “It’s very early, but Fred Hutch recently received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial, and it’s unclear whether it will be successful. This will be a long, multi-year process — should it progress, we would be open to working with other organizations in health care and life sciences that might also be interested in similar efforts.”

Amazon has deepened its presence in the health-care industry in recent years. The company in 2020 launched an online pharmacy, it has ramped up its telehealth service, called Amazon Care, and it has sought to develop at-home medical diagnostics.

A secretive research and development group inside Amazon, known as Grand Challenge, initially oversaw the cancer vaccine effort, according to Business Insider, which cited people familiar with the matter. It’s now under the purview of a cancer research team reporting to Amazon’s vice president of devices, Robert Williams, Business Insider reported.

WATCH: Andy Jassy’s priority is to chart a next generation path for growth, says Madron’s McIlwain



Source

Inside Wealth: Markets are underpricing the risk of Middle East pullback in AI, says tech investor Jack Selby
Technology

Inside Wealth: Markets are underpricing the risk of Middle East pullback in AI, says tech investor Jack Selby

A potential pullback by Middle East sovereign wealth funds could drain hundreds of billions of dollars from the artificial intelligence boom and threaten key data center projects, according to tech investor Jack Selby. Middle East investors — including sovereign wealth funds and government entities — account for roughly a quarter of global investments committed to […]

Read More
Jim Cramer crowns Alphabet the hyperscale earnings winner, sees more upside ahead
Technology

Jim Cramer crowns Alphabet the hyperscale earnings winner, sees more upside ahead

CNBC’s Jim Cramer didn’t hesitate to crown Alphabet as the clear winner in Wednesday night’s barrage of Big Tech earnings. “The Google call – Alphabet was an extraordinary call,” Jim said on ” Squawk on the Street ” on Thursday. “I think with the stock at $370 its going to right to $400,” he added. […]

Read More
Jim Cramer: Don’t let Meta’s post-earnings plunge scare you out of the stock
Technology

Jim Cramer: Don’t let Meta’s post-earnings plunge scare you out of the stock

CNBC’s Jim Cramer said Meta Platforms ‘ post-earnings decline isn’t a reason to jump ship on the stock. Shares are headed for their worst session in six months after a spending outlook raise sent the Facebook parent down over 9% Thursday. Still, Cramer remains a firm believer in CEO Mark Zuckerberg’s vision for the company. […]

Read More